[Notes to editors]

1. About SJ733

SJ733 is a novel inhibitor of *Plasmodium falciparum* ATPase4 (PfATP4), a critical ion channel for sodium regulation in the parasite that causes malaria. As a result of this mechanism, SJ733 can clear parasites very rapidly. The clinical candidate SJ733 was developed by a consortium of researchers in academic and non-profit organizations in the U.S. including St. Jude, the University of California, Rutgers University, and the University of South Florida.

2. About Research Hospital

St. Jude Children's Research Hospital (St. Jude) is leading the way the world understands, treats and cures childhood cancer and other life-threatening diseases. It is the only National Cancer Institute-designated Comprehensive Cancer Center devoted solely to children. Treatments developed at St. Jude have helped push the overall childhood cancer survival rate from 20 percent to 80 percent since the hospital opened more than 50 years ago. St. Jude is working to increase the overall survival rate for childhood cancer to 90 percent in the next decade. St. Jude freely shares the breakthroughs it makes, and every child saved at St. Jude means doctors and scientists worldwide can use that knowledge to save thousands more children. Families never receive a bill from St. Jude for treatment, travel, housing and food—because all a family should worry about is helping their child live. For further information, please visit www.stjude.org or follow St. Jude at @stjuderesearch

3. About Medicines for Malaria Venture

Medicines for Malaria Venture (MMV) is a leading non-profit public–private partnership in the field of malaria, aiming to reduce the burden of malaria in disease-